Acyclic Nucleoside Phosphonates: The Art of the Prodrug
Pharmaceutical Fronts · 01.06.2026 · 08 (02) · e67-e91
DOI: 10.1055/a-2833-6667 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Fronts, erschienen am 01.06.2026. Verfasst von Qingwen Zhang.
Abstract (Originalsprache)
AbstractAcyclic nucleoside phosphonates (ANPs) represent a new dimension for the treatment of DNA viruses and retrovirus infections. Besides the prominent antiviral activity, ANPs have also demonstrated other interesting biological activities, such as antineoplastic and antiparasitic. Due to the presence of characteristic phosphonate functionality, ANPs rely heavily on prodrug approaches for their oral bioavailability and targeted delivery. This article will first longitudinally review the representative parent ANPs and ANP prodrugs in each of the four structural categories (i.e., HPMP, PME, PMP, and other series), focusing on the prodrug design rationales employed, resulting effects on pharmacokinetics and biological activities, as well as clinical relevance as appropriate. Then, the prodrug approaches employed for the design of ANP prodrugs will be horizontally reviewed in a dedicated section. Finally, current advances and future directions of the drug discovery of ANPs and their prodrugs will be discussed in perspective.
Zitieren
APA
Zhang, Q. (2026). Acyclic Nucleoside Phosphonates: The Art of the Prodrug. Pharmaceutical Fronts, 08(02), e67-e91. https://doi.org/10.1055/a-2833-6667
Vancouver
Zhang Q. Acyclic Nucleoside Phosphonates: The Art of the Prodrug. Pharmaceutical Fronts. 2026;08(02):e67-e91. doi:10.1055/a-2833-6667
BibTeX
@article{Zhang2026,
author = {Zhang, Qingwen},
title = {Acyclic Nucleoside Phosphonates: The Art of the Prodrug},
journal = {Pharmaceutical Fronts},
year = {2026},
volume = {08},
number = {02},
pages = {e67--e91},
doi = {10.1055/a-2833-6667}
}
EUVIMED